BlackRock
NRIX icon

BlackRock’s Nurix Therapeutics NRIX Stock Holding History

BlackRock’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$138M Buy
8,925,642
+50,448
+0.6% +$836K ﹤0.01% 1899
2025
Q4 		$168M Buy
8,875,194
+2,112,608
+31% +$30.3M ﹤0.01% 1790
2025
Q3 		$62.5M Sell
6,762,586
-46,112
-0.7% -$479K ﹤0.01% 2370
2025
Q2 		$77.6M Sell
6,808,698
-1,177,195
-15% -$12.7M ﹤0.01% 2213
2025
Q1 		$94.9M Buy
7,985,893
+310,221
+4% +$5.19M ﹤0.01% 2018
2024
Q4 		$145M Buy
7,675,672
+494,137
+7% +$11.3M ﹤0.01% 1856
2024
Q3 		$161M Buy
7,181,535
+361,520
+5% +$8.19M ﹤0.01% 1784
2024
Q2 		$142M Buy
6,820,015
+2,239,601
+49% +$34.9M ﹤0.01% 1824
2024
Q1 		$67.3M Sell
4,580,414
-63,322
-1% -$681K ﹤0.01% 2280
2023
Q4 		$47.9M Buy
4,643,736
+125,182
+3% +$858K ﹤0.01% 2500
2023
Q3 		$35.5M Sell
4,518,554
-823
-0% -$7.51K ﹤0.01% 2612
2023
Q2 		$45.1M Buy
4,519,377
+228,237
+5% +$2.33M ﹤0.01% 2543
2023
Q1 		$38.1M Buy
4,291,140
+148,612
+4% +$1.55M ﹤0.01% 2629
2022
Q4 		$45.5M Buy
4,142,528
+419,438
+11% +$5.06M ﹤0.01% 2537
2022
Q3 		$48.5M Buy
3,723,090
+367,743
+11% +$5.82M ﹤0.01% 2455
2022
Q2 		$42.5M Buy
3,355,347
+830,704
+33% +$9.42M ﹤0.01% 2600
2022
Q1 		$35.4M Sell
2,524,643
-23,218
-0.9% -$412K ﹤0.01% 2789
2021
Q4 		$73.8M Buy
2,547,861
+64,288
+3% +$1.95M ﹤0.01% 2404
2021
Q3 		$74.4M Buy
2,483,573
+396,957
+19% +$12.3M ﹤0.01% 2399
2021
Q2 		$55.4M Buy
2,086,616
+269,927
+15% +$7.92M ﹤0.01% 2631
2021
Q1 		$56.5M Buy
1,816,689
+646,715
+55% +$24.5M ﹤0.01% 2541
2020
Q4 		$38.5M Buy
1,169,974
+500,176
+75% +$16.6M ﹤0.01% 2629
2020
Q3 		$23.4M Buy
+669,798
New +$16.9M ﹤0.01% 2772

Other funds holding NRIX

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock's NRIX Position: Q1 2026 in Review

BlackRock increased its Nurix Therapeutics (NRIX) stake by 0.57% in Q1 2026, buying an estimated $836K and bringing the position to 8,925,642 shares worth $138M. The position accounts for ﹤0.01% of the portfolio, ranked #1899.

BlackRock first reported a position in NRIX in Q3 2020 and has held it in 23 quarters since. The position peaked at $168M in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • BlackRock held 8,925,642 shares of Nurix Therapeutics worth $138M as of Q1 2026.
  • BlackRock bought 50,448 Nurix Therapeutics shares in Q1 2026, an estimated $836K.
  • Nurix Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #1899 holding.
  • BlackRock first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • BlackRock's Nurix Therapeutics position peaked at $168M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.